☆ 4.5 Article

Impact of diabetes duration on left ventricular mass regression with empagliflozin

ESC HEART FAILURE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Cardiac & Cardiovascular Systems

Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study

Suzanne Arnold et al.

Summary: This study found a high prevalence and 3-year incidence of vascular complications in patients with relatively short T2D duration globally, emphasizing the importance of early risk-factor modification. Higher HbA1c levels and smoking were associated with an increased risk of both incident micro-and macrovascular complications.

AMERICAN HEART JOURNAL (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

Avivit Cahn et al.

Summary: The study found that higher HbA(1c) levels were associated with an increased risk of cardiovascular and renal outcomes, particularly in patients with multiple risk factors. However, the benefits of dapagliflozin were observed in all subgroups regardless of baseline HbA(1c) levels.

DIABETES CARE (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Association of Baseline HbA(1c) With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

Avivit Cahn et al.

Summary: Higher baseline HbA(1c) levels are associated with increased risks of cardiovascular and renal outcomes, particularly in the population with multiple risk factors (MRF). However, dapagliflozin showed benefits in reducing the risk of cardiovascular death/HHF, HHF, and cardiorenal outcomes across all subgroups regardless of baseline HbA(1c) levels.

DIABETES CARE (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials

Nitish K. Dhingra et al.

Summary: Recent studies have shown the efficacy of SGLT2 inhibitors in preventing and treating heart failure by reversing left ventricular remodelling, as seen through the results of a systematic review and meta-analysis of RCTs comparing SGLT2 inhibitors versus placebo.

ESC HEART FAILURE (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials

Nitish K. Dhingra et al.

Summary: Recent large RCTs have shown that SGLT2i treatment can reduce left ventricular mass as assessed by cMRI, suggesting a potential mechanism for preventing and treating heart failure.

ESC HEART FAILURE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial

Muthiah Vaduganathan et al.

Summary: Empagliflozin delays insulin initiation and reduces the need for substantial increases in insulin dose in patients with type 2 diabetes and cardiovascular disease, while also facilitating sustained reductions in insulin requirements over time.

DIABETES OBESITY & METABOLISM (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program

Tamara K. Young et al.

Summary: The study assessed the effects of canagliflozin on cardiovascular and kidney outcomes in type 2 diabetes patients with different disease complexity, and found that the drug provided consistent cardiovascular and renal protection across subgroups defined by baseline treatment intensity, duration of diabetes, and HbA(1c) levels.

DIABETOLOGIA (2021)

添加到收藏夹

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Duration of Diabetes and Incident Heart Failure The ARIC (Atherosclerosis Risk In Communities) Study

Justin B. Echouffo-Tcheugui et al.

Summary: This study found that longer duration of diabetes is associated with an increased risk of incident heart failure. The association was stronger among younger individuals, those with poorer glycemic control, higher body mass index, women, and Blacks. The study suggests that delaying diabetes onset may help prevent heart failure, and interventions targeting individuals with long-standing diabetes may improve heart failure outcomes.

JACC-HEART FAILURE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial

Harpreet S. Bajaj et al.

DIABETES OBESITY & METABOLISM (2020)

添加到收藏夹

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The EMPA-HEART CardioLink-6 Randomized Clinical Trial

Subodh Verma et al.

CIRCULATION (2019)

添加到收藏夹

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

S. D. Wiviott et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Review Endocrinology & Metabolism

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

Subodh Verma et al.

DIABETOLOGIA (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Increased left ventricular mass index is present in patients with type 2 diabetes without ischemic heart disease

Jelena P. Seferovic et al.

SCIENTIFIC REPORTS (2018)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control

Silvio E. Inzucchi et al.

CIRCULATION (2018)

添加到收藏夹

Article Medicine, General & Internal

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study

Alexander J. M. Brown et al.

BMC CARDIOVASCULAR DISORDERS (2017)

添加到收藏夹

Article Medicine, General & Internal

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Review Chemistry, Medicinal

Empagliflozin in the treatment of type 2 diabetes: evidence to date

Jay H. Shubrook et al.

DRUG DESIGN DEVELOPMENT AND THERAPY (2015)

添加到收藏夹

Article Endocrinology & Metabolism

Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes

Sophia Zoungas et al.

DIABETOLOGIA (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population

Kazuo Eguchi et al.

AMERICAN JOURNAL OF CARDIOLOGY (2008)

添加到收藏夹

Article Endocrinology & Metabolism

The significant effect of diabetes duration on coronary heart disease morality - The Framingham Heart Study

CS Fox et al.

DIABETES CARE (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.